Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

357 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.
Glidden DV, Amico KR, Liu AY, Hosek SG, Anderson PL, Buchbinder SP, McMahan V, Mayer KH, David B, Schechter M, Grinsztejn B, Guanira J, Grant RM. Glidden DV, et al. Among authors: buchbinder sp. Clin Infect Dis. 2016 May 1;62(9):1172-7. doi: 10.1093/cid/ciw022. Epub 2016 Jan 20. Clin Infect Dis. 2016. PMID: 26797207 Free PMC article. Clinical Trial.
Herpes zoster and human immunodeficiency virus infection.
Buchbinder SP, Katz MH, Hessol NA, Liu JY, O'Malley PM, Underwood R, Holmberg SD. Buchbinder SP, et al. J Infect Dis. 1992 Nov;166(5):1153-6. doi: 10.1093/infdis/166.5.1153. J Infect Dis. 1992. PMID: 1308664
Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load.
Celum CL, Buchbinder SP, Donnell D, Douglas JM Jr, Mayer K, Koblin B, Marmor M, Bozeman S, Grant RM, Flores J, Sheppard HW. Celum CL, et al. Among authors: buchbinder sp. J Infect Dis. 2001 Jan 1;183(1):23-35. doi: 10.1086/317658. Epub 2000 Dec 8. J Infect Dis. 2001. PMID: 11106536
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
Lee D, Graham BS, Chiu YL, Gilbert PB, McElrath MJ, Belshe RB, Buchbinder SP, Sheppard HW, Koblin BA, Mayer KH, Keefer MC, Mulligan MJ, Celum CL. Lee D, et al. Among authors: buchbinder sp. J Infect Dis. 2004 Sep 1;190(5):903-7. doi: 10.1086/423284. Epub 2004 Jul 29. J Infect Dis. 2004. PMID: 15295694 Clinical Trial.
357 results